Endo announces presentation of Xiaflex for Peyronie’s disease at the North Central Section of the American Urological Association

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced  that a presentation related to Peyronie’s disease, or PD, and Xiaflex (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the North Central Section of the American Urological Association (AUA) annual meeting, taking place October 15-18, 2025. Details are as follows

Title; Collagenase Clostridium Histolyticum (CCH) for Ventral Curvature (VC) of the Penis Due to Peyronie’s Disease (PD): Updated Results From a Noninterventional, Retrospective, Multicenter Study

• Authors: Matthew J. Ziegelmann, Billy H. Cordon, Majdee M. Islam Alexander J. Tatem,  Richard C. Bennett, MD; Faysal A. Yafi, Petar Bajic et al.

This Phase IV multicenter, noninterventional, retrospective study evaluated the effectiveness and safety of CCH in adult men with PD and ventral curvature (VC). Researchers reviewed medical charts of patients aged 18 and older diagnosed with VC and a palpable plaque, treated with CCH between 2014 and each site’s study start date. The primary endpoint was percent change in penile VC, while secondary endpoints included mean degree change in penile VC and the proportion of patients achieving at least 30% improvement in penile VC from baseline to last visit.

No serious or severe treatment-related adverse events were reported, and there were no cases of urethral involvement or injury. These updated findings reinforce that CCH is effective and well tolerated in men with PD and VC, supporting its continued use as a nonsurgical treatment option for this population.

“These updated results align with previous findings and further demonstrate that CCH is both effective and well tolerated in men with Peyronie’s disease and ventral curvature,” said Dr. Peter Bajic, Associate Professor of Urology and Director of Men’s Health at Cleveland Clinic’s Glickman Urological Institute and presenting author of the presentation. “This consistency is encouraging for both clinicians and patients seeking nonsurgical treatment options.”